Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $3.4 million.

  • C4 Therapeutics' Other Non-Current Assets changed 0.0% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.4 million for FY2024, which is 0.0% changed from last year.
  • Per C4 Therapeutics' latest filing, its Other Non-Current Assets stood at $3.4 million for Q3 2025, which was down 0.0% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Other Non-Current Assets peaked at $3.5 million during Q3 2023, and registered a low of $1.3 million during Q2 2021.
  • Its 5-year average for Other Non-Current Assets is $3.1 million, with a median of $3.3 million in 2021.
  • Per our database at Business Quant, C4 Therapeutics' Other Non-Current Assets plummeted by 5048.51% in 2021 and then skyrocketed by 15697.49% in 2022.
  • C4 Therapeutics' Other Non-Current Assets (Quarter) stood at $3.3 million in 2021, then changed by 0.0% to $3.3 million in 2022, then grew by 5.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024, then changed by 0.0% to $3.4 million in 2025.
  • Its Other Non-Current Assets was $3.4 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.4 million in Q1 2025.